PSNL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Personalis Inc (PSNL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company has recently secured Medicare coverage for its NeXT Personal test, which is a positive catalyst, but its financial performance is weak, with significant YoY declines in revenue, net income, and gross margin. Additionally, technical indicators and trading sentiment do not suggest a strong upward momentum. Given the investor's profile and the current data, holding off on buying is the prudent choice.
The MACD is negative and contracting, RSI is neutral at 43.986, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 7.565), but there is no strong technical signal for a buy.
Medicare coverage for the NeXT Personal cancer test, which could drive growth and expand patient access.
Weak financial performance in Q3 2025, with significant declines in revenue (-43.62%), net income (-44.61%), EPS (-62.50%), and gross margin (-61.20%).
In Q3 2025, revenue dropped to $14.495M (-43.62% YoY), net income dropped to -$21.652M (-44.61% YoY), EPS dropped to -0.24 (-62.50% YoY), and gross margin dropped to 13.2% (-61.20% YoY).
Guggenheim raised the price target from $12 to $13 and maintained a Buy rating, reflecting optimism about the company's growth potential despite weak financials.
